Jakafi 10 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FGES3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,663
Award facts
- Contract value 100% obligated
- $12,663.27 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $12,663.27 to DMS Pharmaceutical Group Inc. for 60-count bottles of Jakafi 10 mg tablets. This firm fixed-price delivery order was issued on January 22, 2026, with an ultimate completion date of January 23, 2026, and will be performed in Park Ridge, Illinois. No set-aside designation was used for this award. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected as the awardee through its competitive capability in unrestricted federal procurement.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. That parent contract, valued at $499,999,999 with a completion date of December 31, 2036, positions DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy designed to support recurring pharmaceutical and medical supply needs of Department of Defense healthcare facilities worldwide. The current delivery order represents a routine pharmaceutical procurement supporting military healthcare operations, consistent with DMS Pharmaceutical Group's demonstrated performance across the diverse therapeutic categories and product lines supplied through the prime vendor contract.
Quick answers
Who was awarded contract SPE2DR26FGES3?
SPE2DR26FGES3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26FGES3 worth?
The government has obligated $12,663 on SPE2DR26FGES3.
Is contract SPE2DR26FGES3 an order under another contract?
Yes. SPE2DR26FGES3 is a delivery order under SPE2DR25D9312, an indefinite delivery contract.
Was contract SPE2DR26FGES3 competed?
The extent of competition for SPE2DR26FGES3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award